Nerandomilast attenuates idiopathic inflammatory myopathy-associated interstitial lung disease via inhibiting proliferation and differentiation of B cells - PubMed
4 days ago
- #IIM-ILD
- #Nerandomilast
- #B cells
- Nerandomilast, a PDE4B inhibitor, shows therapeutic potential for idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD).
- The study used an IIM-ILD mouse model to evaluate Nerandomilast's effects on muscle inflammation, pulmonary fibrosis, and inflammation.
- Nerandomilast inhibited B cell accumulation, proliferation, and differentiation into plasma cells, reducing anti-Jo-1 autoantibody positivity.
- Mechanistically, Nerandomilast elevated cAMP levels in lung tissue and inhibited pro-survival/activation pathways (PI3K/AKT, NF-κB, STAT3) in B cells.
- The findings suggest Nerandomilast as a promising candidate for treating IIM-ILD by modulating B cell activity.